

IN VITRO CHARACTERIZATION AND EVALUATION OF TRANSDERMAL DRUG DELIVERY SYSTEM FOR METOPROLOL TARTARATE

DR.B.ANILREDDY

For author affiliations, see end of text

This paper is available online at www.jprhc.in

ABSTRACT

Transdermal delivery system bypass the hepatic first pass metabolism and avoid drug degradation due to gastrointestinal pH, enzymes etc., minimize plasma level fluctuations and extend the drug activity besides improving patient compliance. Transdermal films of metoprolol tartarate were prepared using polymers such as ethyl cellulose, poly vinyl alcohol, eudragit RL100, eudragit L100. Di-n-butylphthalate was used as plasticizer. The study was undertaken to report the film forming properties of polymers used and *in vitro* drug release from the prepared monolithic matrices. Effect of drug loading on the drug release rate was also studied. The transdermal films were prepared using solvent casting method. These films were evaluated for Thickness, Percent moisture loss, Percent moisture absorption, Drug content, Weight variation and

folding endurance. *In-vitro* drug release kinetics was studied using Franz-diffusion cell. Drug release followed zero order kinetics. Drug loading at different concentrations found to have less effect on the film forming properties of the constituent polymers. Results have shown enhanced flux per unit time across rat skin. In conclusion combination of ethyl cellulose, poly vinyl alcohol, eudragit RL100, eudragit L100 and Di-n-butylphthalate can potentially be optimized to develop an effective transdermal drug delivery system for metoprolol tartarate.

Key words: Metoprolol Tartarate, Transdermal Delivery system, Eudragit RL 100, Eudragit L 100.

INTRODUCTION

In recent years, considerable attention has been focused on the development of new drug delivery systems. Transdermal drug delivery system has been in existence for a long time. In past, the most commonly applied systems were topically applied creams and ointments for dermatological disorders. Drugs administered in the form of tablets, capsules, injectables and ointment etc., usually produce wide ranging fluctuation in drug concentrations in the blood stream and tissues and factors such as repetitive dosing and unpredictable absorption send lead to the concept of controlled drug delivery system or therapeutic system.

Transdermal systems provide drug systemically at a predictable rate and maintain the rate for extended periods of time thus eliminating numerous problems associated with oral products such as unpredictable or reduced bioavailability, enhanced first patches across the freshly excised rat skin.

MATERIALS AND METHODS

Metoprolol tartarate was obtained as the gift sample from the Madras Pharmaceuticals Ltd, Chennai. Ethyl Cellulose,

pass hepatic metabolism, relatively short residence time, dose dumping and dosing inflexibility

Metoprolol tartrate is a beta blocker used in the treatment of hypertension, undergoes hepatic first pass metabolism reductions in low bioavailability 40-50% given by oral route and the low dose (100 -200mg) daily. Hence it is suitable for formulation as a transdermal patch. The present study was undertaken to formulate the matrix type transdermal patches of metoprolol tartarate. The polymers used for the preparation of monolithic matrix were Ethyl Cellulose (EC), Poly Vinyl Alcohol (PVA), Eudragit RL100, Eudragit L100 and Di-n-butylphthalate used as plasticizer. The investigations intend to report the film forming properties of the selected polymers and also to study *in-vitro* drug release from the prepared transdermal

Eudragit RL100; Eudragit L100 was obtained as the gift sample from the Glenmark pharmaceutical Ltd, Mumbai. Di-n-butylphthalate and poly vinyl alcohol purchased from the local

vendors. Apart from these all other chemicals used were analytical grade reagents.

Table 1: Composition of Transdermal Patches

Formulation	EC	PVA	Eudragit RL 100	Eudragit L 100	Plasticizer (Di-n-butylphthalate)
F1	-	5	5	-	0.12gm
F2	4.5	-	-	5.5	0.12gm
F3	4	2	3	1	0.12gm
F4	2	1.5	2.5	4	0.12gm
F5	3.5	-	6.5	-	0.12gm

Experimental

Preparation of monolithic matrix films

The matrix type transdermal patches containing metoprolol tartrate prepared using different ratios of Eudragit RL100 and Eudragit L100. The polymers in different ratios were increased to a total weight of 400 mg and dissolved in phosphate buffer pH 7.4. Metoprolol tartrate (50 mg) was added slowly to the polymer solution and mixed thoroughly to obtain a uniform solution. Di-n-butyl-phthalate was used as a plasticizer. The polymeric solution of the drug was poured onto the mercury surface (25cm²) and dried at room temperature in dust free environment. After 24 hours the film were cut into a pieces of 5cm² area and a backing membrane of aluminum foil was glued on. The transdermal films were stored in desiccator until further use.

Evaluation of the films

The evaluation of the films was performed for the Thickness, Percent moisture loss, Percent moisture absorption, Drug content, Folding endurance, Weight variation

Thickness

Thickness of the films was measured at six different points using a screw gauge and average thickness of three films was found out.

Percent moisture absorption

The percent moisture absorption test was carried out to check the physical stability and integrity of the films at high humid conditions. In the present study the moisture absorption capacities of the films were determined in the following manner.

The films were placed in desiccator containing saturated solution of aluminum chloride, keeping the humidity inside the desiccator at 79.5% RH. After 3 days the films were taken and weighed the percentage moisture absorption of three films was found.

Percentage cumulative drug release vs time

$$\text{Percent moisture absorption} = \frac{\text{Final weight} - \text{initial weight}}{\text{Initial weight}} \times 100$$

Percent Moisture Loss

This test was also carried to check the integrity of films at dry condition. Three films of 5 square centimeter area was cut and weighed accurately and kept in a desiccator containing fused anhydrous calcium chloride.

After 72 hours the films were removed and weighed. Average percentage moisture loss of three films was found out.

$$\text{Percent moisture loss} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100$$

Drug Content

A film of 5 square centimeter area was cut and dissolved in phosphate buffer. After adding suitable reagent and dilution, optical density was found out at 223nm. Average drug content of three transdermal films were determined.

Folding Endurance

It was determined by repeatedly folding a small strip of films at the same place till it broke. The number of times, the films could be folded at the same place without breaking gave the value of folding endurance.

Weight Variation

Each film was weighed individually and average weight of three films was found.

In-Vitro Dissolution Studies

In-vitro dissolution studies were carried out in phosphate buffer pH 7.4 for 24 hours. In order to find out the order of release and the mechanism, which was predominantly influences the drug release from membrane, the *in-vitro* drug dissolution data was subjected to the different modes of graphical treatment.

Ex-Vivo Permeation Studies

Male rats weighting 105 – 120 gm free from any visible sign of disease were selected. Having a depilatory preparation hair removed from the skin of full thickness was excised from the rat. This was mounted on the donor compartment. The Transdermal patch was placed over it.

The permeation study was carried out in the similar manner as that with artificial membrane

RESULTS AND DISCUSSION

In the present study efforts were to prepare transdermal patches of Metoprolol tartrate by using different polymers in different ratios such as Eudragit RL100, Eudragit L100, PVA and EC using different combinations of the above mentioned polymers and the plasticizer used dibutylphthalate.

The prepared formulations were subjected to various physiochemical characteristics such as percent moisture absorption, percent moisture loss, drug content, thickness, folding endurance and weight variation. The release characteristics of formulation were studied in-vitro dissolution studies Ex-vivo studies by using of rat skin.

The formulation F1 has shown the highest percent moisture absorption and percent moisture loss than other formulation. This might be because of the high water permeability of. It also observed that formulation F3 has shown least percent moisture absorption and percent moisture loss which might be due to the low permeability of Eudragit RL 100 to water.

The thickness of the films varied from 16 to 21mm. The minimum standard deviation values assumed that the process used for preparing the drug delivery system is capable of giving reproducible result. This fact is further conformed by drug content and weight uniformity studied. In order to evaluate the flexibility the film were subjected to folding endurance studied. The values in the range that prepared films were observed batches having capability to withstand the mechanical pressure along with good flexibility.

The formulations F1, F2, F3, F4and F5 have shown the drug release for 24 hours to the extent of 99%, 99.04%, 78.08%, 81.84% and 91.04% respectively. The Higuchi's plot has shown the regression value of five formulations in **Table 2** which indicates that the release of drug from the patch was governed by a diffusion mechanism.

Table 2: Regression Values of Formulations

Formulation Code	Regression for Huguchi Plot
F1	0.9882
F2	0.9675
F3	0..9786
F4	0.9626
F5	0.9932




Table 3: INVITRO DRUG RELEASE DATA

Time (hours)	Cumulative % of Drug release (F1)	Cumulative % of Drug release (F2)	Cumulative % of Drug release (F3)	Cumulative % of Drug release (F4)	Cumulative % of Drug release (F5)
1.	67.2	53.52	29.52	23.36	50.4
2.	68.24	54.08	30.08	25.5	51.04
3.	68.8	55.35	30.72	27.04	52.24
4.	70.4	56.0	32.0	29.52	53.52
5.	72.8	57.2	33.84	33.2	54.72
6.	75.0	58.4	36.24	35.04	56.0
7.	80.0	60.24	38.08	36.24	57.2
8.	81.2	67.2	40.0	40.0	59.04
9.	81.8	68.88	42.4	42.4	60.88
10.	83.6	70.08	45.52	44.88	65.2
11.	84.8	72.0	48.56	46.72	67.04
12.	85.5	72.0	49.84	48.86	70.72
13.	86.0	72.8	52.24	51.68	72.0
14.	89.2	76.24	53.52	53.52	72.8
15.	91.0	78.08	54.72	54.72	75.2
16.	91.6	84.0	57.2	57.2	78.08
17.	92.2	85.52	59.68	59.68	79.3
18.	93.5	88.56	62.72	60.88	82.4
19.	95.3	91.68	65.84	65.54	84.24
20.	95.3	92.88	67.04	68.88	85.52
21.	96	94.72	70.08	72.0	86.08
22.	96.5	99.04	72.0	74.4	87.36
23.	97.2	99.04	75.04	77.52	88.56
24.	99.0	99.04	78.08	81.84	91.04

CONCLUSION

Formulation F3 containing was found to best among all batches because of its consistent release rate for 24 hour and extent of drug release was 78.08%.

Ex-vivo permeating studied confirmed that in-vitro drug release data corrected with the ex-vivo data observed in rat skin.

The formulation F3 has achieved the object to extended release reduced frequency of administration, avoids the first pass effect and thus may improve the patient compliance.

REFERENCES

1. Aquill Mohamed.,(2004) "*Matrix Type transdermal drug delivery system of metoprolol tartrate: Skin toxicity and invitro characterization*", Ethiopian Pharmaceutical Journal: 12, P 53 – 60.
2. V.V. Ranade.,(2005) "*The Journal of clinical Pharmacology Drug Delivery System 6 transdermal drug delivery*", Ranade: 32 (5) P 401.
3. Gupta S.P. Jain S.K., (2005) "*Effective and controlled transdermal delivery Metoprolol tartrate*", 67(3), JIPS P 346 – 350.
4. Kusumdevi, Saisivam, S Maria GR, Deepti PU., (2003) "*Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride*", Drug delivery Ind. Pharma 29(5), Page No. 495- 503.
5. Gupta R. Mukhrejee B.,(2003) "*Development and invitro evaluation of ditiach hydrochloride transdermal patches based on providone ethyl cellulose materials*" Vol (1), Drug Dev. Ind. Pharma, 1-7.
6. Gupta S.P. Jain S.K.,(2004) "*Development of Matrix, Membrane transdermal drug delivery system for atenolol*" 11(5), P. 281-6.
7. F.K. Earthlink.net / frankoepe / transdermal htm "*transdermal drug delivery*", F.K. 12/14/01 – 1-2.

As the extension of work pharmacokinetic studies, *in-vivo* studies on higher animals and controlled clinical studies on human being can be carried out in future.

ACKNOWLEDGEMENT:

I am thankful to my management of Maheshwara College of Pharmacy for their consistent support and kind cooperation for my work.

8. S.Sridevi and D.R. Krishna.,(1991) "*Transdermal drug delivery systems*" Eastern Pharmacist.
9. Clarks, "*Metoprolol*", Vol. 2 3rd ed., Analysis of Drugs and Poison Page No. 1275 – 76.
10. USP – 26., (2003) "*Metoprolol Tartrate and Hydrochlorothiazide Tablets*" NF 21, USP – 26 Official Monograph P – 1224 – 25.
11. Tortora "*Human Anatomy of Physiology*", X edition, Page 141 – 143.
12. Raymond, C. Rowe, Paul J. Sheskey "*Handbook of Pharmaceutical Exipients*" IV Edition, P (203-4) (297 – 299), (237 – 241) P: (462–467).
13. K.D. Tripathi, "*Metoprolol*" Ed. IX, Medical Pharmacology P, 129.
14. Goodman and Guilman "*Metoprolol*" 10th edition, P – 1982.
15. Srinivas Mutalik, Nayerhabhiath Udupa.,(2006) "*Pharmacological evaluation of Membrane, Moderated transdermal system*", 33(1-2), Chin Exp. Pharmacol, Physiology, Page 17 – 26.

AUTHORS AFFILIATION AND ADDRESS FOR CORRESPONDENCE:

Dr.B.Anilreddy, M.Pharm, Ph.D

MCP, Hyderabad.Email: drbanilreddy@gmail.com